BC Highway Patrol nabs 12 alleged impaired drivers in South OkanaganDear Heloise: Don’t forget to stock up on batteries for Christmas. Most gifts that require batteries don’t have them included. You want to be sure that folks will be able to use the item as soon as they unwrap it. This is especially important for children’s gifts. — Carolyn M., in Canaan, Connecticut Touchscreen sensitivity transitions Dear Heloise: Touchscreens have transitioned from being pressure-sensing to capacitive. Because of this transition, the moisture of your fingertip determines the sensitivity. I find that I need to occasionally lick my fingertip to get the screen to detect my finger, especially in the winter. I even had to do this to sign for a delivery. (I then washed that hand.) Hand lotion is not good as it leaves a residue. There are touch-screen stylus pens that may also work. — David B., New Ulm, Minnesota People are also reading... A green tip Dear Heloise: A green tip I learned is not to put anything down the drain/toilet that you don’t absolutely have to. Things that go in the trash also go to the landfill, but things that go down the drain must go through several caustic processes that take up a great deal of energy to get the waste to the point that it can actually be disposed of in the landfill. — Annie H., Missoula, Montana Being more environmentally aware Dear Heloise: A couple of months ago, my husband and I were vacationing in Canada, and we were very impressed by how our neighbors in the north recycle items. We were also happily surprised that they take cloth bags to grocery stories and use paper bags instead of plastic. Everyone looks at an environmentally friendly and sustainable way of life as the correct way to live. Why can’t this country do the same thing? We have graffiti everywhere. People throw trash in the ocean, which kills thousands of sea life that mistake it for food. Our public parks often have overflowing trash barrels. We all live on one planet, and as far as I can tell, it’s everyone’s responsibility to “take out the trash.” We need to end plastic bag use in America and teach our children that being careless and throwing garbage in the ocean is not acceptable. We all need to show more pride in our surroundings and remember that we don’t own Earth. We are merely stewards of Earth. — Rita B., Mount Clemens, Michigan Rita, I think Americans have been slow to adopt environmental changes, and unless our government does more to encourage people to conserve, recycle, and take better care of the world around us, things won’t change. I’m hoping this will start with people at a grassroots level. — Heloise Indoor pollution Dear Heloise: Indoor pollution can be caused by many factors such as cigarette smoke, gas stoves, and off-gases from new furniture, paint, wallpaper or carpeting. If you find it easier to breathe outside of your home, you may have developed an allergy from indoor pollution. There are some things you can do, and the first is to see a doctor to isolate what it is that you’re allergic to, in order to stop the rash, coughing or other irritations. We finally found out my son was allergic to cigarettes, so we quit smoking. His lungs cleared up. — Victoria H., Eugene, Oregon Send a money-saving or time-saving hint to Heloise@Heloise.com . Be the first to know Get local news delivered to your inbox!

Ulta Beauty (NASDAQ:ULTA) Downgraded to Market Perform Rating by William Blair

SVG Summit Technology Exhibits Preview, Part 2WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") TVGN , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have." William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, "We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed." The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen's ability to develop additional product candidates, including through use of Tevogen's ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen's future clinical trials; and Tevogen's ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the "Business Combination") on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

New pro-European coalition approved in Romania amid period of political turmoil"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.Quest Partners LLC decreased its position in shares of Chipotle Mexican Grill, Inc. ( NYSE:CMG – Free Report ) by 44.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,220 shares of the restaurant operator’s stock after selling 7,414 shares during the period. Quest Partners LLC’s holdings in Chipotle Mexican Grill were worth $531,000 at the end of the most recent reporting period. Other large investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. raised its holdings in shares of Chipotle Mexican Grill by 53.7% during the 1st quarter. Advisors Asset Management Inc. now owns 455 shares of the restaurant operator’s stock worth $1,323,000 after acquiring an additional 159 shares in the last quarter. Morse Asset Management Inc purchased a new stake in Chipotle Mexican Grill during the first quarter valued at $294,000. SVB Wealth LLC lifted its position in Chipotle Mexican Grill by 3.7% during the first quarter. SVB Wealth LLC now owns 140 shares of the restaurant operator’s stock valued at $407,000 after purchasing an additional 5 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its stake in shares of Chipotle Mexican Grill by 2.1% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 633 shares of the restaurant operator’s stock worth $1,840,000 after buying an additional 13 shares in the last quarter. Finally, Meiji Yasuda Life Insurance Co increased its holdings in shares of Chipotle Mexican Grill by 235.8% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 460 shares of the restaurant operator’s stock worth $1,337,000 after buying an additional 323 shares during the last quarter. 91.31% of the stock is owned by institutional investors. Chipotle Mexican Grill Stock Up 3.4 % Shares of CMG stock opened at $62.01 on Friday. The company’s 50 day moving average is $58.45 and its 200 day moving average is $81.06. The firm has a market cap of $84.49 billion, a price-to-earnings ratio of 57.95, a PEG ratio of 2.41 and a beta of 1.26. Chipotle Mexican Grill, Inc. has a 52-week low of $43.66 and a 52-week high of $69.26. Wall Street Analyst Weigh In A number of brokerages recently commented on CMG. BMO Capital Markets increased their price target on shares of Chipotle Mexican Grill from $55.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Robert W. Baird raised their price objective on Chipotle Mexican Grill from $62.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Citigroup cut their target price on Chipotle Mexican Grill from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. Piper Sandler raised their price target on Chipotle Mexican Grill from $59.00 to $60.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Stephens reiterated an “equal weight” rating and set a $65.00 price objective on shares of Chipotle Mexican Grill in a research report on Tuesday, November 12th. Ten research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Chipotle Mexican Grill has a consensus rating of “Moderate Buy” and a consensus target price of $65.27. Check Out Our Latest Stock Report on Chipotle Mexican Grill Insider Buying and Selling at Chipotle Mexican Grill In other news, insider Curtis E. Garner sold 15,750 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $55.02, for a total transaction of $866,565.00. Following the completion of the sale, the insider now owns 473,514 shares in the company, valued at approximately $26,052,740.28. This represents a 3.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Also, Director Robin S. Hickenlooper sold 1,790 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $56.38, for a total value of $100,920.20. Following the transaction, the director now owns 41,510 shares in the company, valued at approximately $2,340,333.80. This trade represents a 4.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last ninety days, insiders sold 33,290 shares of company stock valued at $1,866,023. 1.02% of the stock is currently owned by insiders. Chipotle Mexican Grill Profile ( Free Report ) Chipotle Mexican Grill, Inc, together with its subsidiaries, owns and operates Chipotle Mexican Grill restaurants. It sells food and beverages through offering burritos, burrito bowls, quesadillas, tacos, and salads. The company also provides delivery and related services its app and website. It has operations in the United States, Canada, France, Germany, and the United Kingdom. Featured Articles Want to see what other hedge funds are holding CMG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chipotle Mexican Grill, Inc. ( NYSE:CMG – Free Report ). Receive News & Ratings for Chipotle Mexican Grill Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chipotle Mexican Grill and related companies with MarketBeat.com's FREE daily email newsletter .